Status:
COMPLETED
Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI)
Lead Sponsor:
Massachusetts General Hospital
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this research study is to see if a specific kind of MRI, called Ultrasmall Superparamagnetic Iron Oxide Magnetic Resonance Imaging (USPIO MRI), which uses an FDA-approved therapeutic ag...
Detailed Description
* On the first day, study participants will undergo 2 MRI examinations. A scan will be done prior to administration of the contrast agent (Feraheme) and then a second scan immediately after administra...
Eligibility Criteria
Inclusion
- Locally resectable pancreatic mass present on one or more pre-operative imaging modalities
- Must demonstrate no evidence of distant metastases as assessed by chest/abdomen/pelvis CT scan
- Deemed eligible for resection with curative intent by a treating surgeon who is listed as an investigator on this study
- 18 years of age or older
- No uncontrolled serious medical or psychiatric illness
- Women of childbearing potential must not be pregnant or lactating
Exclusion
- Known allergy to iron or dextran
- Pregnant or lactating
- Counter-indication to MRI, such as the presence of metallic prostheses or implanted metal device
- Sickle cell disease or hemoglobinopathy
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2013
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00920023
Start Date
July 1 2008
End Date
February 1 2013
Last Update
July 25 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114